Indicators of Drug Or Alcohol Abuse Or Misuse: Behavioral Physical
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0. -
Supporting Information a Analysed Substances
Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 List of contents: Tab. A1 Detailed list and classification of analysed substances. Tab. A2 List of selected MS/MS parameters for the analytes. Tab. A1 Detailed list and classification of analysed substances. drug of therapeutic doping agent analytical standard substance abuse drug (WADA class)* supplier (+\-)-amphetamine ✓ ✓ S6 stimulants LGC (+\-)-methamphetamine ✓ S6 stimulants LGC (+\-)-3,4-methylenedioxymethamphetamine (MDMA) ✓ S6 stimulants LGC methylhexanamine (4-methylhexan-2-amine, DMAA) S6 stimulants Sigma cocaine ✓ ✓ S6 stimulants LGC methylphenidate ✓ ✓ S6 stimulants LGC nikethamide (N,N-diethylnicotinamide) ✓ S6 stimulants Aldrich strychnine S6 stimulants Sigma (-)-Δ9-tetrahydrocannabinol (THC) ✓ ✓ S8 cannabinoids LGC (-)-11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) S8 cannabinoids LGC morphine ✓ ✓ S7 narcotics LGC heroin (diacetylmorphine) ✓ ✓ S7 narcotics LGC hydrocodone ✓ ✓ Cerillant® oxycodone ✓ ✓ S7 narcotics LGC (+\-)-methadone ✓ ✓ S7 narcotics Cerillant® buprenorphine ✓ ✓ S7 narcotics Cerillant® fentanyl ✓ ✓ S7 narcotics LGC ketamine ✓ ✓ LGC phencyclidine (PCP) ✓ S0 non-approved substances LGC lysergic acid diethylamide (LSD) ✓ S0 non-approved substances LGC psilocybin ✓ S0 non-approved substances Cerillant® alprazolam ✓ ✓ LGC clonazepam ✓ ✓ Cerillant® flunitrazepam ✓ ✓ LGC zolpidem ✓ ✓ LGC VETRANAL™ boldenone (Δ1-testosterone / 1-dehydrotestosterone) ✓ S1 anabolic agents (Sigma-Aldrich) -
ADHD: Substance Abuse
1/13/2012 Overview of Mental Health Medications for Children and Adolescents Module 6 Medications and Drugs of Abuse 1 1967 Now Alcohol Alcohol Marijuana Marijuana Cocaine Cocaine Methamphetamine Crank LSD LSD Rohypnol/GHB Quaaludes Inhalants Glue Ecstasy Designer drugs Prescription drugs 2 ADHD: Substance Abuse Children with untreated ADHD are twice as likely to develop substance abuse by age 18-20 than those who were treated Treatment with stimulants in adolescents with ADHD and comorbid substance abuse improves the ADHD and does not worsen the substance abuse disorder 3 1 1/13/2012 Drug Lingo Resources www.noslang.com www.teenchatterdecoder.com 4 2001 2003 2004 2008 Cocaine 967.6 kg 379.6 1308.1 1016.1 kg kg kg Heroin 15.8 kg 60 kg 39.3 kg 3.3 kg Meth 77.4 kg 88 kg 83.9 kg 65 kg Meth Labs 51 226 261 78 Ecstasy Tablets 52951 8393 5 Cocaine Bulk cocaine transported into state – crack made locally Primary sources – Texas and California Heroin Sources of supply – Chicago, New York and Southwest Purity in GA ranges between 52-65% Greater Hispanic involvement www.dea.gov 6 2 1/13/2012 Drug Use in Georgia Methamphetamine Atlanta, Dalton, Gainesville showing increases as well as southwest and eastern counties Increased availability of ICE in Atlanta area Club drugs MDMA, GHB and ketamine readily available (gyms, college campuses and associated ‘hang outs’ LSD usually around school settings – imported from West Coast by US postal service or express mail Emerging trend – ‘candy tripping’ – combining LSD and MDMA -
Appendix D: Important Facts About Alcohol and Drugs
APPENDICES APPENDIX D. IMPORTANT FACTS ABOUT ALCOHOL AND DRUGS Appendix D outlines important facts about the following substances: $ Alcohol $ Cocaine $ GHB (gamma-hydroxybutyric acid) $ Heroin $ Inhalants $ Ketamine $ LSD (lysergic acid diethylamide) $ Marijuana (Cannabis) $ MDMA (Ecstasy) $ Mescaline (Peyote) $ Methamphetamine $ Over-the-counter Cough/Cold Medicines (Dextromethorphan or DXM) $ PCP (Phencyclidine) $ Prescription Opioids $ Prescription Sedatives (Tranquilizers, Depressants) $ Prescription Stimulants $ Psilocybin $ Rohypnol® (Flunitrazepam) $ Salvia $ Steroids (Anabolic) $ Synthetic Cannabinoids (“K2”/”Spice”) $ Synthetic Cathinones (“Bath Salts”) PAGE | 53 Sources cited in this Appendix are: $ Drug Enforcement Administration’s Drug Facts Sheets1 $ Inhalant Addiction Treatment’s Dangers of Mixing Inhalants with Alcohol and Other Drugs2 $ National Institute on Alcohol Abuse and Alcoholism’s (NIAAA’s) Alcohol’s Effects on the Body3 $ National Institute on Drug Abuse’s (NIDA’s) Commonly Abused Drugs4 $ NIDA’s Treatment for Alcohol Problems: Finding and Getting Help5 $ National Institutes of Health (NIH) National Library of Medicine’s Alcohol Withdrawal6 $ Rohypnol® Abuse Treatment FAQs7 $ Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) Keeping Youth Drug Free8 $ SAMHSA’s Center for Behavioral Health Statistics and Quality’s (CBHSQ’s) Results from the 2015 National Survey on Drug Use and Health: Detailed Tables9 The substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15.10 Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the United States, their relative abuse potential, and likelihood of causing dependence when abused. -
A Molecular Phylogeny of the Solanaceae
TAXON 57 (4) • November 2008: 1159–1181 Olmstead & al. • Molecular phylogeny of Solanaceae MOLECULAR PHYLOGENETICS A molecular phylogeny of the Solanaceae Richard G. Olmstead1*, Lynn Bohs2, Hala Abdel Migid1,3, Eugenio Santiago-Valentin1,4, Vicente F. Garcia1,5 & Sarah M. Collier1,6 1 Department of Biology, University of Washington, Seattle, Washington 98195, U.S.A. *olmstead@ u.washington.edu (author for correspondence) 2 Department of Biology, University of Utah, Salt Lake City, Utah 84112, U.S.A. 3 Present address: Botany Department, Faculty of Science, Mansoura University, Mansoura, Egypt 4 Present address: Jardin Botanico de Puerto Rico, Universidad de Puerto Rico, Apartado Postal 364984, San Juan 00936, Puerto Rico 5 Present address: Department of Integrative Biology, 3060 Valley Life Sciences Building, University of California, Berkeley, California 94720, U.S.A. 6 Present address: Department of Plant Breeding and Genetics, Cornell University, Ithaca, New York 14853, U.S.A. A phylogeny of Solanaceae is presented based on the chloroplast DNA regions ndhF and trnLF. With 89 genera and 190 species included, this represents a nearly comprehensive genus-level sampling and provides a framework phylogeny for the entire family that helps integrate many previously-published phylogenetic studies within So- lanaceae. The four genera comprising the family Goetzeaceae and the monotypic families Duckeodendraceae, Nolanaceae, and Sclerophylaceae, often recognized in traditional classifications, are shown to be included in Solanaceae. The current results corroborate previous studies that identify a monophyletic subfamily Solanoideae and the more inclusive “x = 12” clade, which includes Nicotiana and the Australian tribe Anthocercideae. These results also provide greater resolution among lineages within Solanoideae, confirming Jaltomata as sister to Solanum and identifying a clade comprised primarily of tribes Capsiceae (Capsicum and Lycianthes) and Physaleae. -
January 2020 Sanctions List Full
GLOBAL LIST OF INELIGIBLE PERSONS Period of Date of Discipline Date of Ineligibility Lifetime Infraction Name Nationality Role Sex Discipline 2 Sanction Disqualification ADRV Rules ADRV Notes Description Birth 1 Infraction until Ban? Type of results ABAKUMOVA, Maria 15/01/1986 RUS athlete F Javelin Throws 21/08/2008 4 years 17/05/2020 From 21.08.08 to No Doping Presence,Use Dehydrochloromethyltestos In competition test, XXIX Olympic ineligibility 20.08.12 terone games, Beijing, CHN ABDOSH, Ali 25/08/1987 ETH athlete M Long Distance 24/12/2017 4 years 04/02/2022 Since 24-12-2017 No Doping Presence,Use Salbutamol In competition test, 2017 Baoneng (3000m+) ineligibility Guangzhou Huangpu Marathon , ACHERKI, Mounir 09/02/1981 FRA athlete M 1500m Middle Distance 01/01/2014 4 years 15/04/2021 Since 01-01-2014 No Doping Use,Possessio Use or Attempted Use by an IAAF Rule 32.2(b) Use of a prohibited (800m-1500m) ineligibility n Athlete of a Prohibited substance ADAMCHUK, Mariya 29/05/2000 UKR athlete F Long Jump Jumps 03/06/2018 4 years 16/08/2022 Since 03.06.18 No Doping Presence,Use Benzoylecgonine In competition test, XXI Cross Citta ineligibility di Novi Ligure, Novi Ligure, ITA ADEKOYA, Kemi 16/01/1993 BRN athlete F 400m Sprints (400m or 24/08/2018 4 years 25/11/2022 Since 24.08.18 No Doping Presence,Use Stanozolol Out-of-competition test, Jakarta, IDN Hurdles less) ineligibility ADELOYE, Tosin 07/02/1996 NGR athlete F 400m Sprints (400m or 24/07/2015 8 years 23/07/2023 Since 24-07-2015 No Doping Presence,Use Exogenous Steroids In competition -
How to Anesthetize Donkeys for Surgical Procedures in the Field
DRUGS AND ANESTHESIA How to Anesthetize Donkeys for Surgical Procedures in the Field Lori A. Bidwell, DVM, Diplomate ACVA Author’s address: Ross University School of Veterinary Medicine, PO Box 334, St. Kitts, West Indies; e-mail: [email protected]. © 2010 AAEP. 1. Introduction ing a local block where a catheter will be placed and Donkeys are an important part of the work force in making a small skin incision with a surgical blade much of the world. Practitioners working with before placing an intravenous catheter is recom- donkeys in the United States and those participat- mended. Intubation is more difficult because of ing in equitarian initiatives abroad should under- caudal angulation of the larynx, a pharyngeal diver- stand the difference between donkeys and horses in ticulum, excess pharyngeal mucosa, and long paired relation to anesthesia. Although it is tempting to laryngeal saccules. Additionally, nasal intubation 1 treat a donkey like a horse, there are important is complicated by narrow nasal passages. Drug differences in relation to handling and drug doses. metabolism is elevated in donkeys compared with Additionally, it is important to understand alterna- horses, resulting in the use of higher doses and more 2–6 tive anesthetic protocols because a practitioner may frequent dosing intervals. The only known ex- be limited to minimal or alternative drugs when ception to this is the administration of guaifenesin, working in a developing country. which seems to require lower dosing because respi- ratory arrest is easy to achieve when using doses 7 2. Behavior and Physiology appropriate for a horse. A tame donkey can be easy to handle but a feral or minimally handled donkey can be frustrating. -
3.2.1.2 Lean Pre-Mixed Combustion 3.2.1.2-1 Introduction
3.2.1.2 Lean Pre-Mixed Combustion 3.2.1.2-1 Introduction Gas turbine designers are continually challenged to improve cycle effi ciency while maintaining or reducing emissions. This challenge is made more diffi cult by the fact that these are often confl icting goals. The path to improved effi ciency is higher working fl uid temperatures, but higher temperatures promote NOx formation and at 2,800 F the threshold for thermal NOx formation is reached. Furthermore, reducing available oxygen to reduce NOx can result in higher carbon monoxide (CO) and unburned hydrocarbon emissions due to incomplete combustion. Moreover, increasing fi ring temperatures above 2,350 F represents a signifi cant materials science challenge.1 To achieve lower pollutant emission rates, a variety of pre-formation and post- formation control technologies have been utilized either individually or in combination, including: • Wet controls (water or steam injection) • Dry combustion controls (lean combustion, reduced residence time, lean premixed combustion, and two-stage rich/lean combustion) • Selective catalytic reduction • SCONOX catalytic absorption • Catalytic combustion (e.g. Xonontm ) • Rich Quench Lean Combustors • CO oxidation catalysts This section of the Handbook focuses on Lean Premixed (LPM) combustion, a pre-formation control strategy that has become the standard technique employed by gas turbine original equipment manufacturers (OEM), particularly for natural gas applications. OEMs have developed processes that use air as a diluent to reduce combustion fl ame temperatures and reduce NOx by premixing fuel and air before they enter the combustor. This lean premixed combustion process is referred to by a variety of trade names including General Electric’s and Siemens-Westinghouse’s Dry Low NOx (DLN) processes, Rolls-Royce’s Dry Low Emissions (DLE) process and Solar Turbines’ SoLo NOx process. -
CRIME AWARENESS BULLETIN Joint Base Lewis-Mcchord Directorate of Emergency Services Police Intelligence / Crime Analysis Unit
CRIME AWARENESS BULLETIN Joint Base Lewis-McChord Directorate of Emergency Services Police Intelligence / Crime Analysis Unit 30 May 2012 Emerging Drug Trend First there was K2 (Spice) and the slew of synthetic cannabinoids. Then came bath salts; they were new and they were legal. These drugs were available and sold as over-the-counter products in an international web-based marketplace. Many of them were sold in head shops and medical marijuana clinics in the United States. But now these synthetics are all banned, well, most of them anyway. But into the fray now comes "Pump-It Powder," an "enhanced plant vitamin." It's the latest synthetic drug to be manufactured and sold under the ruse of a substance, "not intended for human consumption." With myriad bath salts and plant food products available in the marketplace, uncertainty already reigns. No one quite knows what is in these synthetics. The Internet is full of supposition, but it is not clear at all what manufacturers are putting into their final products. Nevertheless, a great deal of discussion has centered on the role of geranamine as primary constituent of Pump-It. Geranamine is also known as methylhexanamine, an old-time amphetamine-related stimulant and decongestant that is found naturally in the geranium plant, hence its name. Methylhexanamine is a legal substance; it is not scheduled by the DEA. The drug has not been widely studied. It was patented in 1944 and for the most part has been dormant since that time. But in the world of energy drinks and aphrodisiac potions, methylhexanamine has been a prime player. -
Accidental Doping. Prevention Strategies
RevisiónPedro Manonelles, et al. Accidental doping. Prevention strategies Pedro Manonelles1, Oriol Abellán Aynés2, Daniel López-Plaza2, Marta Fernández Calero3, Carmen Daniela Quero Calero1, Luis Andreu Caravaca1, José Luis Terreros4 1Cátedra Internacional de Medicina del Deporte. Universidad Católica San Antonio de Murcia (UCAM). 2Facultad de Deporte. Universidad Católica San Antonio de Murcia (UCAM). 3Facultad de Ciencias de la Salud. Universidad Católica San Antonio de Murcia (UCAM). 4Agencia Española de protección de la Salud en el Deporte (AEPSAD). Recibido: 30.10.2019 Summary Aceptado: 15.11.2019 There is growing consumption of nutritional supplements aimed at improving performance because the number of athletes, mainly amateurs, is growing very significantly. This great demand supposes a market of huge proportions, supposing an economic activity that in Spain reached 920 million Euros in the year 2018. This consumption occurs at all levels of sport, from 13% in global numbers, to 100% in some groups of professional sportsmen and women. However, the use of these substances in very few circumstances is done under the advice of a professional, and the athlete takes them on their own. This fact, with the possibility that the product to be taken may contain prohibited substances that do not appear on the labeling, means that an adverse analytical finding can occur in a doping control through so-called ac- cidental doping, which is the use of adulterated or contaminated nutritional supplements containing substances prohibited in sport that have not been declared on the labeling. Key words: Between 11.6% and 25.8% of nutritional supplements contaminated with anabolic androgenic steroids have been found to exist. -
DMAA Ingestion
Bloomer RJ, et al., J Altern Complement Integr Med 2018, 4: 057 DOI: 10.24966/ACIM-7562/100057 HSOA Journal of Alternative, Complementary & Integrative Medicine Review aid, notwithstanding widespread anecdotal reports of improved exer- 1,3-Dimethylamylamine cise performance and focus following DMAA ingestion. While reports have documented an association between DMAA ingestion and ad- (DMAA): A Brief History verse events, it remains unclear as to the causal role of DMAA, in particular considering the fact that specific to the reported events, and Review of Anecdotal DMAA was often used in combination with other dietary ingredients, prescription medications or recreational drugs. This review discuss- and Laboratory Findings es the history of DMAA, anecdotal and laboratory findings pertaining to its use, and its use today within the dietary supplement market. Richard J Bloomer1*, Nicholas JG Smith1, Damien C Moore1 Keywords: Dietary supplement; Ergogenic aid; Stimulant; Weight and Charles R Yates2 loss 1Center for Nutraceutical and Dietary Supplement Research, School of Health Studies, University of Memphis, Memphis, Tennessee, USA Introduction 2College of Pharmacy, University of Tennessee Health Science Center, While the ingredient referred to as DMAA was once a highly Memphis, Tennessee, USA utilized ingredient in sport nutrition and weight loss dietary supple- ments, it has been the target of much controversy. Also known by the names 2-amino-4-methylhexane, 1,3-dimethylamylamine, 1,3-di- methylpentylamine, methylhexanamine, 4-methyl-2-hexylamine and “Geranamine™” (as well as others), this agent has been largely re- moved from the marketplace due primarily to concerns regarding its overall safety profile. In particular, a variety of case reports describing individuals experiencing adverse events following the use of DMAA alone or within dietary supplements have fueled these concerns. -
Role and Advantageousness of Ketamine
a & hesi C st lin e ic n a A l Journal of Anesthesia and Clinical f R o e l s e a a n Weinbroum, J Anesth Clin Res 2018, 9:5 r r c u h o J Research DOI: 10.4172/2155-6148.1000827 ISSN: 2155-6148 Review Article Open Access Role and Advantageousness of Ketamine in Obese and Non-Obese Patients: Peri-Interventional Considerations Avi A Weinbroum* Department of Research and Development, Tel Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel *Corresponding author: Avi A Weinbroum, Department of Research and Development, Tel Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Tel: +972-3-5440904; E-mail: [email protected] Received date: May 16, 2018; Accepted date: May 25, 2018; Published date: May 29, 2018 Copyright: ©2018 Weinbroum AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Obese and morbidly obese patients are a growing group of individuals that generates medical, social and economic problems worldwide. They undergo various interventions that require anesthesia and/or analgesia. Despite their healthy look, these individuals are graded at high ASA physical status, mainly because of their impaired respiratory and cardiovascular conditions, and the metabolic changes their body undergoes. Opioids are the default drugs for perioperative analgesia. Nevertheless, their use has reached a frightening epidemic-like condition worldwide.